Latest Updates

Baricitinib in Juvenile Idiopathic Arthritis: An International, Phase 3, Randomised, Double-blind, Placebo-controlled, Withdrawal, Efficacy, and Safety Trial

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease

Galapagos Receives Positive CHMP Opinion for Filgotinib European Label Update Based on Testicular Function Safety Data

FDA Approves Deucravacitinib for Adults with Moderate-to-Severe Plaque Psoriasis

Secukinumab Receives Expanded Approvals in EU for Use in childhood Arthritic Conditions

FDA Approves Baricitinib As First and Only Systemic Medicine for Adults with Severe Alopecia Areata